Transplantation Biology Research Center, Department of Surgery, Massachusetts General Hospital, Boston, MA.
Am J Transplant. 2013 Oct;13(10):2558-66. doi: 10.1111/ajt.12423. Epub 2013 Aug 22.
We have previously shown that tolerance of kidney allografts across a full major histocompatibility complex (MHC) barrier can be induced in miniature swine by a 12-day course of high-dose tacrolimus. However, that treatment did not prolong survival of heart allografts across the same barrier. We have now tested the effect of cotransplanting an allogeneic heart and kidney from the same MHC-mismatched donor using the same treatment regimen. Heart allografts (n = 3) or heart plus kidney allografts (n = 5) were transplanted into MHC-mismatched recipients treated with high-dose tacrolimus for 12 days. As expected, all isolated heart allografts rejected by postoperative day 40. In contrast, heart and kidney allografts survived for >200 days with no evidence of rejection on serial cardiac biopsies. Heart/kidney recipients lost donor-specific responsiveness in cell-mediated lympholysis and mixed-lymphocyte reaction assays, were free of alloantibody and exhibited prolonged survival of donor, but not third-party skin grafts. Late (>100 days) removal of the kidney allografts did not cause acute rejection of the heart allografts (n = 2) and did not abrogate donor-specific unresponsiveness in vitro. While kidney-induced cardiac allograft tolerance (KICAT) has previously been demonstrated across a Class I disparity, these data demonstrate that this phenomenon can also be observed across the more clinically relevant full MHC mismatch. Elucidating the renal element(s) responsible for KICAT could provide mechanistic information relevant to the induction of tolerance in recipients of isolated heart allografts as well as other tolerance-resistant organs.
我们之前已经证明,在小型猪中,通过 12 天的高剂量他克莫司治疗,可以诱导对完整主要组织相容性复合物(MHC)屏障的肾同种异体移植物的耐受。然而,该治疗并不能延长相同屏障下的心脏同种异体移植物的存活时间。我们现在已经使用相同的治疗方案测试了同种异体心脏和肾脏共移植来自同一 MHC 错配供体的效果。心脏同种异体移植物(n = 3)或心脏加肾脏同种异体移植物(n = 5)被移植到接受高剂量他克莫司治疗 12 天的 MHC 错配受者中。正如预期的那样,所有单独的心脏同种异体移植物在术后第 40 天被排斥。相比之下,心脏和肾脏同种异体移植物存活超过 200 天,连续心脏活检均无排斥迹象。心脏/肾脏受者在细胞介导的淋巴溶解和混合淋巴细胞反应测定中失去了供体特异性反应性,没有同种抗体,并且表现出供体但不是第三方皮肤移植物的延长存活。晚期(> 100 天)去除肾脏同种异体移植物不会导致心脏同种异体移植物的急性排斥(n = 2),并且不会在体外消除供体特异性无反应性。虽然已经在 I 类差异的情况下证明了肾诱导的心脏同种异体移植物耐受(KICAT),但这些数据表明,这种现象也可以在更具临床相关性的完整 MHC 错配中观察到。阐明 KICAT 的肾脏要素可能为诱导孤立心脏同种异体移植物以及其他耐受抵抗器官的受者的耐受提供与机制相关的信息。